AME

Business Profile & Competitive Position

AMETEK, Inc. operates in the Industrials sector, specifically the Electrical Equipment & Parts industry. The company is organized into two segments. The Electronic Instruments Group (EIG) designs and manufactures advanced analytical, test and measurement instruments for the process, aerospace, power and industrial markets. The Electromechanical Group (EMG) supplies precision motion control solutions, highly engineered medical components and devices, thermal management systems, specialty metals and electrical interconnects to aerospace and defense, medical, automation and other industrial markets.

The financial profile supports the idea that AMETEK competes on engineering specialization rather than commodity pricing. The net margin is 20.0%, and return on equity is 14.5%. A 20.0% net margin in an industrial parts business suggests durable pricing power, likely driven by customized products, long qualification cycles and customer switching costs. The 14.5% ROE implies reasonable but not exceptional capital efficiency, which is consistent with a business that must reinvest in manufacturing assets, R&D and acquisitions to maintain its position. For 2025, AMETEK reported sales of $7,401.1 million, up 6.6% from 2024, with diluted earnings per share of $6.40, up 7.9%. The company also recorded record operating income, net income, orders and backlog, which points to demand momentum at the time of the filing.

Financial Posture

AMETEK’s current market capitalization is $55.5 billion, and it trades at a P/E ratio of 35.2. That multiple sits well above the level typical of mature industrial conglomerates, so the market is pricing in sustained growth and margin stability. The 20.0% net margin and 14.5% ROE provide some justification, but at a 35.2 P/E the company needs to keep expanding earnings at a strong pace to hold that valuation. The beta of 0.97 indicates the stock has historically moved roughly in line with the broader market, so it has not offered significant defensive isolation.

The growth targets in AMETEK’s own disclosures frame this valuation: the company targets high-single-digit annual sales growth and double-digit annual EPS growth, along with strong cash flow generation and a superior return on total capital. If execution aligns with those targets, the premium P/E can make sense. If growth or margin decelerates, the multiple could compress quickly. As of the most recent snapshot, the stock price was $241.91, the RSI was 45.2 and the 50-day EMA was $244.69, leaving the price just below that short-term trend line.

Strategic Priorities & Outlook

AMETEK’s most recent 10-K filing lays out a clear operational agenda. The company is focused on executing the AMETEK Growth Model, which aims for high-single-digit annual sales growth, double-digit annual EPS growth, strong cash flow and superior return on total capital. It also emphasizes Operational Excellence through lean manufacturing, global sourcing, Design for Six Sigma, Value Engineering/Value Analysis, growth kaizens, digitalization and artificial intelligence.

Acquisitions are central to the strategy. From 2021 through December 31, 2025, AMETEK completed 15 acquisitions representing approximately $1.8 billion in annualized sales. In 2025 alone, the company spent $933.2 million in cash, net of cash acquired, to purchase Kern, a provider of high-precision machining and optical inspection solutions, and FARO Technologies, a 3D measurement and imaging solutions business. These deals fit the stated goal of adding adjacent, complementary technologies aligned with secular growth themes.

Global expansion is another priority. AMETEK maintains best-cost manufacturing facilities in China, Czechia, Malaysia, Mexico and Serbia to stay close to customers and support international growth. The geographic mix is meaningful: in 2025, 52% of EIG net sales and 42% of EMG net sales went to customers outside the United States. As of December 31, 2025, the company employed approximately 22,500 people.

Macro & Geopolitical Exposure

Because AMETEK sits in Electrical Equipment & Parts within Industrials, it is exposed to the macro currents that shape global manufacturing and infrastructure spending. These include industrial automation demand, aerospace and defense budgets, power and process capital expenditures, and medical device investment. The industry also faces input cost pressure from metals, energy, semiconductors and electronic components, as well as potential supply-chain constraints.

With roughly half of segment sales going outside the United States, currency fluctuations are a recurring factor. A stronger U.S. dollar can dampen reported overseas earnings, while a weaker dollar can provide a tailwind. Trade policy, tariffs and export controls are also relevant, especially because aerospace, defense and semiconductor-related end markets can face cross-border restrictions. The manufacturing footprint in China, Czechia, Malaysia, Mexico and Serbia gives AMETEK local production capability, but it also ties the company to regional economic conditions and geopolitical developments.

Regulatory standards are another consideration. Medical, aerospace and power-industry products must meet strict safety, quality and environmental requirements, which can affect product development timelines and compliance costs. Commodity price swings and freight costs can move margins in either direction, making operational discipline an ongoing necessity.

Recent Developments

Pre-earnings coverage dominated the recent news flow. On November 2, 2026, Zacks published “AMETEK to Post Q3 Earnings: Time to Buy, Sell or Hold the Stock?” On October 29, 2026, Zanks released “Unlocking Q3 Potential of Ametek (AME): Exploring Wall Street Estimates for Key Metrics.” Two days earlier, on October 27, 2026, Zacks also ran “Ametek (AME) Earnings Expected to Grow: Should You Buy?” These headlines show elevated attention ahead of the November 3, 2026 earnings report.

Separately, on October 27, 2026, Defense World reported that Citizens Financial Group Inc. RI purchased 5,502 shares of AMETEK. While a single institutional trade is not decisive, it adds to the pre-earnings narrative of institutional positioning. The consensus EPS estimate for the upcoming quarter is $2.11.

Earnings Behavior & Post-Earnings Drift

AMETEK has an impeccable recent earnings record. Over the last eight reported quarters, the company beat consensus earnings estimates in all eight quarters, a 100% beat rate, with an average earnings surprise of 4%. Despite that consistency, the average 5-day price move after earnings across those quarters was only 0.46%, classified as flat drift. In other words, beats have been reliable, but the market has not consistently rewarded them with directional follow-through.

The most recent four quarters illustrate the mixed reaction pattern:

• On August 4, 2026, AMETEK reported actual EPS of $2.09 versus an estimate of $1.99, a 5.0% surprise. The stock rose 0.28% the next day and 0.89% over the following five sessions.
• On April 30, 2026, actual EPS was $1.97 versus $1.90, a 3.7% surprise. The next-day move was -2.13%, and the five-day drift was -0.33%.
• On February 3, 2026, actual EPS came in at $2.01 versus $1.94, a 3.6% surprise. The next-day change was -0.48%, but the five-day drift reversed to +1.83%.
• On October 30, 2025, actual EPS was $1.89 versus $1.76, a 7.4% surprise. The stock rose 1.91% the next day, yet drifted -0.54% over the following five sessions.

The takeaway from this history is that AMETEK typically clears the bar, but the post-earnings price path is uneven. The market’s real expectation may already be embedded before the release, and a beat alone has not guaranteed a sustained rally. With the next report scheduled for November 3, 2026 before the open, traders will be watching whether the company can extend its streak while also gauging whether guidance is strong enough to move the stock beyond its recent $241.91 level.

For a more complete picture of how institutional analysts currently view AMETEK—covering detailed model assumptions, target ranges and risk factors beyond the numbers above—review the full institutional verdict on the platform.